Sami-Ramzi Leyh-Bannurah

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5342005/publications.pdf

Version: 2024-02-01

39 papers	1,059 citations	567144 15 h-index	414303 32 g-index
40 all docs	40 docs citations	40 times ranked	2022 citing authors

#	Article	IF	Citations
1	Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. European Urology, 2016, 69, 393-396.	0.9	368
2	Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records. JCO Clinical Cancer Informatics, 2018, 2, 1-9.	1.0	150
3	Local Therapy Improves Survival in Metastatic Prostate Cancer. European Urology, 2017, 72, 118-124.	0.9	100
4	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. Prostate, 2017, 77, 686-693.	1.2	33
5	Survival benefit of local versus no local treatment for metastatic prostate cancerâ€"Impact of baseline PSA and metastatic substages. Prostate, 2018, 78, 753-757.	1.2	27
6	Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations. World Journal of Urology, 2019, 37, 469-479.	1.2	25
7	Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort. Clinical Genitourinary Cancer, 2017, 15, e809-e817.	0.9	21
8	Populationâ€Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. Prostate, 2017, 77, 105-113.	1.2	21
9	Anterior Localization of Prostate Cancer Suspicious Lesions in 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies. Journal of Urology, 2018, 200, 1035-1040.	0.2	21
10	Limitations of Elastography Based Prostate Biopsy. Journal of Urology, 2016, 195, 1731-1736.	0.2	20
11	Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. World Journal of Urology, 2018, 36, 1067-1072.	1.2	18
12	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 81.e17-81.e24.	0.8	18
13	Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. European Urology, 2016, 70, 429-435.	0.9	16
14	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. Journal of Sexual Medicine, 2017, 14, 876-882.	0.3	16
15	Primary Gleason pattern upgrading in contemporary patients with D'Amico lowâ€risk prostate cancer: implications for future biomarkers and imaging modalities. BJU International, 2017, 119, 692-699.	1.3	16
16	Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 527.e21-527.e28.	0.8	16
17	A proposal of a new nomogram for predicting upstaging in contemporary Dâ€™Amico low-risk prostate cancer patients. World Journal of Urology, 2017, 35, 189-197.	1.2	15
18	North American Populationâ€Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. Prostate, 2017, 77, 542-548.	1.2	15

#	Article	IF	Citations
19	Controversial evidence for the use of HistoScanningâ„¢ in the detection of prostate cancer. World Journal of Urology, 2015, 33, 1993-1999.	1.2	14
20	Adherence of the indication to European Association of Urology guideline recommended pelvic lymph node dissection at a high-volume center: Differences between open and robot-assisted radical prostatectomy. European Journal of Surgical Oncology, 2015, 41, 1547-1553.	0.5	13
21	Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 243-249.	0.8	11
22	Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer. World Journal of Urology, 2021, 39, 81-88.	1.2	11
23	Improvement of quality of life and symptom burden after robot-assisted radical prostatectomy in patients with moderate to severe LUTS. Scientific Reports, 2021, 11, 16757.	1.6	11
24	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e141-e149.	0.9	10
25	Feasibility of robot-assisted radical prostatectomy in men at senior age â‰¥75 years: perioperative, functional, and oncological outcomes of a high-volume center. Aging Male, 2022, 25, 8-16.	0.9	10
26	Perioperative and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center. Journal of Urology, 2021, 206, 308-318.	0.2	9
27	Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions. Journal of Urology, 2022, 207, 333-340.	0.2	8
28	Impact of preoperative risk on metastatic progression and cancerâ€specific mortality in patients with adverse pathology at radical prostatectomy. BJU International, 2017, 120, 666-672.	1.3	7
29	The impact of age on pathological insignificant prostate cancer rates in contemporary robot-assisted prostatectomy patients despite active surveillance eligibility. Minerva Urology and Nephrology, 2022, 74, .	1.3	7
30	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e9-239.e15.	0.8	6
31	Impact of obesity on perioperative, functional and oncological outcomes after robotic-assisted radical prostatectomy in a high-volume center. World Journal of Urology, 2022, 40, 1419-1425.	1.2	6
32	Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience. European Urology Focus, 2019, 5, 568-576.	1.6	5
33	Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer. World Journal of Urology, 2021, 39, 3747-3754.	1.2	5
34	Two-year quality of life after robot-assisted radical prostatectomy according to pentafecta criteria and cancer of the prostate risk assessment (CAPRA-S). Scientific Reports, 2022, 12, 244.	1.6	5
35	Live surgery in reconstructive urology: evaluation of the surgical outcome and educational benefit of the international meeting on reconstructive urology (IMORU). World Journal of Urology, 2019, 37, 2533-2539.	1.2	2
36	Oncologic impact of concomitant prostate cancer characteristics at the time of radical cystoprostatectomy for bladder cancer: a population-based analysis. Aging Male, 2022, 25, 54-61.	0.9	1

#	Article	IF	Citations
37	The Dilemma of Misclassification Rates in Senior Patients With Prostate Cancer, Who Were Treated With Robot-Assisted Radical Prostatectomy: Implications for Patient Counseling and Diagnostics. Frontiers in Surgery, 2022, 9, 838477.	0.6	1
38	Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores. World Journal of Urology, 2022, , .	1.2	1
39	Reply By Authors. Journal of Urology, 2021, 206, 317-318.	0.2	0